Mechanisms, chemical structures and drug metabolism

Lance R. Pohi, N. R. Pumford, J. L. Martin

Research output: Contribution to journalArticle

Abstract

From the studies that have been done by many laboratories over the last 2 decades, it is now clear that the toxicities produced by many drugs are due to their reactive metabolites. It is thought that, in many cases, reactive metabolites cause toxicity by binding covalently to tissue proteins. However, until recently it was difficult to identify these protein targets. Due to the development of an immunochemical approach, this problem has been overcome, as is illustrated here by studies that have been conducted on the metabolic basis of the idiosyncratic hepatitis caused by the inhalation anaesthetic halothane. The major problem to solve in the future will be to determine how protein adduct formation leads to toxicity. It is possible that protein adduct formation may alter an important cellular function or may lead to immunopathology, as is thought to occur in the case of halothane hepatitis. If an allergic reaction is suspected, purified protein targets of reactive metabolites can serve as antigens for identifying sensitized individuals. This information can be used to prevent not only an allergic reaction to the drug, but possibly cross-reactions to other drugs that are structurally related. Another important application of these studies is the design of safer alternative drugs that will not produce structurally similar toxic reactive metabolites

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalEuropean Journal of Haematology
Volume57
Issue numberSUPPL.60
DOIs
StatePublished - 1996

Fingerprint

Pharmaceutical Preparations
Proteins
Hypersensitivity
Inhalation Anesthetics
Poisons
Cross Reactions
Halothane
Hepatitis
Antigens
Halothane Hepatitis

Keywords

  • Autoantibodies
  • Drug allergy
  • Halothane hepatitis
  • Idiosyncratic drug toxicity
  • Protein adducts
  • Reactive metabolites

ASJC Scopus subject areas

  • Hematology

Cite this

Mechanisms, chemical structures and drug metabolism. / Pohi, Lance R.; Pumford, N. R.; Martin, J. L.

In: European Journal of Haematology, Vol. 57, No. SUPPL.60, 1996, p. 98-104.

Research output: Contribution to journalArticle

Pohi, Lance R. ; Pumford, N. R. ; Martin, J. L. / Mechanisms, chemical structures and drug metabolism. In: European Journal of Haematology. 1996 ; Vol. 57, No. SUPPL.60. pp. 98-104.
@article{0643f10aeab84f9293ebdacfb9f8e72f,
title = "Mechanisms, chemical structures and drug metabolism",
abstract = "From the studies that have been done by many laboratories over the last 2 decades, it is now clear that the toxicities produced by many drugs are due to their reactive metabolites. It is thought that, in many cases, reactive metabolites cause toxicity by binding covalently to tissue proteins. However, until recently it was difficult to identify these protein targets. Due to the development of an immunochemical approach, this problem has been overcome, as is illustrated here by studies that have been conducted on the metabolic basis of the idiosyncratic hepatitis caused by the inhalation anaesthetic halothane. The major problem to solve in the future will be to determine how protein adduct formation leads to toxicity. It is possible that protein adduct formation may alter an important cellular function or may lead to immunopathology, as is thought to occur in the case of halothane hepatitis. If an allergic reaction is suspected, purified protein targets of reactive metabolites can serve as antigens for identifying sensitized individuals. This information can be used to prevent not only an allergic reaction to the drug, but possibly cross-reactions to other drugs that are structurally related. Another important application of these studies is the design of safer alternative drugs that will not produce structurally similar toxic reactive metabolites",
keywords = "Autoantibodies, Drug allergy, Halothane hepatitis, Idiosyncratic drug toxicity, Protein adducts, Reactive metabolites",
author = "Pohi, {Lance R.} and Pumford, {N. R.} and Martin, {J. L.}",
year = "1996",
doi = "10.1111/j.1600-0609.1996.tb01654.x",
language = "English (US)",
volume = "57",
pages = "98--104",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "SUPPL.60",

}

TY - JOUR

T1 - Mechanisms, chemical structures and drug metabolism

AU - Pohi, Lance R.

AU - Pumford, N. R.

AU - Martin, J. L.

PY - 1996

Y1 - 1996

N2 - From the studies that have been done by many laboratories over the last 2 decades, it is now clear that the toxicities produced by many drugs are due to their reactive metabolites. It is thought that, in many cases, reactive metabolites cause toxicity by binding covalently to tissue proteins. However, until recently it was difficult to identify these protein targets. Due to the development of an immunochemical approach, this problem has been overcome, as is illustrated here by studies that have been conducted on the metabolic basis of the idiosyncratic hepatitis caused by the inhalation anaesthetic halothane. The major problem to solve in the future will be to determine how protein adduct formation leads to toxicity. It is possible that protein adduct formation may alter an important cellular function or may lead to immunopathology, as is thought to occur in the case of halothane hepatitis. If an allergic reaction is suspected, purified protein targets of reactive metabolites can serve as antigens for identifying sensitized individuals. This information can be used to prevent not only an allergic reaction to the drug, but possibly cross-reactions to other drugs that are structurally related. Another important application of these studies is the design of safer alternative drugs that will not produce structurally similar toxic reactive metabolites

AB - From the studies that have been done by many laboratories over the last 2 decades, it is now clear that the toxicities produced by many drugs are due to their reactive metabolites. It is thought that, in many cases, reactive metabolites cause toxicity by binding covalently to tissue proteins. However, until recently it was difficult to identify these protein targets. Due to the development of an immunochemical approach, this problem has been overcome, as is illustrated here by studies that have been conducted on the metabolic basis of the idiosyncratic hepatitis caused by the inhalation anaesthetic halothane. The major problem to solve in the future will be to determine how protein adduct formation leads to toxicity. It is possible that protein adduct formation may alter an important cellular function or may lead to immunopathology, as is thought to occur in the case of halothane hepatitis. If an allergic reaction is suspected, purified protein targets of reactive metabolites can serve as antigens for identifying sensitized individuals. This information can be used to prevent not only an allergic reaction to the drug, but possibly cross-reactions to other drugs that are structurally related. Another important application of these studies is the design of safer alternative drugs that will not produce structurally similar toxic reactive metabolites

KW - Autoantibodies

KW - Drug allergy

KW - Halothane hepatitis

KW - Idiosyncratic drug toxicity

KW - Protein adducts

KW - Reactive metabolites

UR - http://www.scopus.com/inward/record.url?scp=33847573483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847573483&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.1996.tb01654.x

DO - 10.1111/j.1600-0609.1996.tb01654.x

M3 - Article

AN - SCOPUS:33847573483

VL - 57

SP - 98

EP - 104

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - SUPPL.60

ER -